1225218-98-3 Usage
Uses
Used in Pharmaceutical Synthesis:
(R)-Benzyl 3-(pyridin-3-yl)pyrrolidine-1-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals and bioactive compounds. Its pyridine and pyrrolidine rings provide a versatile framework for the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (R)-benzyl 3-(pyridin-3-yl)pyrrolidine-1-carboxylate is used as a chiral building block for the design and synthesis of novel drug candidates. Its unique structure and reactivity enable the creation of molecules with specific biological activities, contributing to drug discovery and development.
Used in Organic Synthesis:
(R)-Benzyl 3-(pyridin-3-yl)pyrrolidine-1-carboxylate is also utilized in organic synthesis as a versatile reagent for the preparation of a wide range of chemical compounds. Its ester functionality and chiral nature make it a valuable component in the synthesis of complex organic molecules with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1225218-98-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,5,2,1 and 8 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1225218-98:
(9*1)+(8*2)+(7*2)+(6*5)+(5*2)+(4*1)+(3*8)+(2*9)+(1*8)=133
133 % 10 = 3
So 1225218-98-3 is a valid CAS Registry Number.
1225218-98-3Relevant academic research and scientific papers
BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES
-
Page/Page column 55, (2010/05/14)
This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preve
BIARYL CARBOXAMIDES
-
Page/Page column 56, (2010/08/04)
This invention provides compounds of Formula (I) which are PAFR antagonists: Formula (I) and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for treating or ameliorating pain, e.g. inflammatory pain and/or nociceptive pain, and for treating or ameliorating autoimmune and/or inflammatory diseases, among other conditions.
